Quantitative Mapping of Mitochondrial Complex I Expression via PET Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a non-invasive means to quantify mitochondrial complex I (MC-I) expression levels in vivo, relying on invasive in vitro assays that require biopsies or surgery, which is clinically undesirable for assessing various diseases linked to MC-I deficiencies.
Innovation Solution
A non-invasive PET imaging method using a PET ligand like 18F-Flurpiridaz, which binds reversibly to MC-I, allowing for quantitative mapping of MC-I expression and myocardial blood flow, enabling in vivo assessment of MC-I levels and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If in vitro assay is used to measure MC-I expression, then measurement precision is improved, but ease of operation deteriorates due to requiring biopsy or surgery
Solution Approach 1:
The patent uses a PET ligand as an intermediary substance that binds to MC-I in living tissue, enabling indirect measurement of MC-I expression through PET imaging. This mediator allows in vivo quantification without direct tissue extraction, resolving the contradiction between measurement precision and ease of operation
Solution Approach 2:
The patent replaces the mechanical invasive procedure (biopsy/surgery) with a non-invasive imaging system (PET scanner). The mechanical system of tissue extraction is substituted by a detection system that measures MC-I expression through the binding of radioligand and subsequent gamma ray detection
2Ease of operation
If in vivo PET imaging with MC-I ligand is used, then ease of operation is improved, but measurement precision may deteriorate due to binding reaction complexity
Solution Approach 1:
The patent performs preliminary kinetic analysis and validation to establish the binding characteristics of the PET ligand to MC-I before clinical application. By pre-characterizing the binding reaction kinetics and validating the imaging protocol, the method ensures measurement precision is maintained despite the complexity of in vivo binding
Solution Approach 2:
The patent uses dynamic PET imaging to capture the time-dependent binding behavior of the ligand to MC-I, providing feedback information about the binding kinetics. This feedback allows for quantitative analysis that accounts for the complex binding reaction, maintaining measurement precision through continuous monitoring and modeling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and precise non-invasive quantification of MC-I expression levels and myocardial blood flow, facilitating the diagnosis of MC-I-related diseases and providing a tool for evaluating therapeutic agents, with potential applications in cardiac and neuropsychiatric disorders.
Implementation Method 1
administering a PET ligand which binds reversibly to MC-I in the tissues of a living subject
Implementation Method 2
imaging the subject with a positron emission tomography (PET) imaging system
Data Source
Figure 1A~1B
Figure 1C
Figure 2A~2B
AI summary
A system and method is provided for processing a positron emission tomography (PET) image of a subject having received a dose of a radiotracer that serves as chemical analog of an MC-I inhibitor. Specifically, the processing may includes identifying portions of the at least one PET image that represent MC-I expression levels.